Three years after severe COVID-19 hospitalization, significant risks of mortality and long-term symptoms persist, impacting overall health and quality of life.
Alnylam reveals positive Phase III results for rare heart disease drug vutrisiran – Pharmaceutical Technology
RNAi therapeutic, vutrisiran is FDA approved for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTR) in adults and is sold under the brand name